This correction is being published to correct the Tables. In Tables 2-4, corrections are underlined.
In Table 2, there was an overlap of 2 individuals included in “others”, which ranged from 12 (8.6%) to 10 (7.1%). In Table 3, 20 other oral cancer patients and 30 other patients with tumors in the head and neck did not present osteoradionecrosis (ORN), and they were added to a total of 139 patients. In Table 4, the incidence of ORN according to each antineoplastic treatment modality in 139 patients, was 10/60 (60.0%) radiotherapy (RT), 6/32 (18.8%) RT+chemotherapy (CT)+surgery, 4/30 (13.3%) RT+surgery, and 4/67 (5.9%) RT+CT. The changes in all tables did not change the order of incidence of the factors; thus, the changes clarify the mathematical doubts of readers without invalidating our study.
The authors apologize for any inconvenience this may have caused.
After correction
Table 2.
Tumor sites in 139 patients irradiated in the head and neck area
| Site | Value |
|---|---|
| Oropharynx | 53 (38.1) |
| Oral cavity | 44 (31.7) |
| Larynx | 20 (14.4) |
| Hypopharynx | 4 (2.9) |
| Nasopharynx | 8 (5.8) |
| Others1 | 10 (7.1) |
1Tumors of the parotid, maxillary sinus, skin, brain, thyroid, and hypophysis.
Values are presented as number (%).
Table 3.
Incidence of ORN in irradiated HCN according to tumor location
| Primary tumor | Value |
|---|---|
| Oral cancer (n=11) | |
| Mouthfloor SCC | 7/10 (70.0) |
| Alveolar ridge SCC | 1/2 (50.0) |
| Buccal mucosa SCC | 2/7 (28.6) |
| Palate adenocarcinoma | 1/9 (11.1) |
| Others oral region 1 | 0/20 (0) |
| Skin SCC | 1/1 (100) |
| Oral cancer+oropharynx cancer | 2/4 (50.0) |
| Nasopharynx cancer | 1/8 (12.5) |
| Oropharynx | 5/48 (10.4) |
| Other 2 | 0/30 (0) |
(ORN: osteoradionecrosis, HCN: head and neck cancer, SCC: squamous cell carcinoma)
1 Other oral cancer: retromolar. tongue, lower lip.
2 Other: breasts, cervical, thyroid, head, hypopharynx, pharynx, larynx.
Values are presented as number (ORN/total tumors) (%).
Table 4.
Incidence of ORN according to antineoplastic treatment
| Radiotherapy | Value |
|---|---|
| Modality | |
| RT | 6/10 (60.0) |
| RT+CT+surgery | 6/32 (18.8) |
| RT+surgery | 4/30 (13.3) |
| RT+CT | 4/67 (5.9) |
| Type of RT | |
| Cobalt/conventional | 10/54 (18.5) |
| IMRT | 8/53 (15.1) |
| 3D-CRT | 1/14 (7.1) |
| Not informed | 1/18 (5.6) |
(ORN: osteoradionecrosis, RT: radiotherapy, CT: chemotherapy, IMRT: intensity-modulated radiation therapy, 3D-CRT: three- dimensional conformal radiation therapy)
Values are presented as number (ORN/antineoplasic treatment) (%).